PLEASANTON, Calif., Nov. 5, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences.
On Wednesday, November 13, the company will participate in the Credit Suisse 2013 Healthcare Conference. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 7:30 a.m., Mountain Standard Time ( 9:30 a.m., Eastern Standard Time). A webcast of the presentation will be available at http://cc.talkpoint.com/cred001/111313a_jw/?entity=70_56TSJIF, or on the company's website at http://www.thoratec.com.
On Thursday, November 14, Thoratec will participate in the Canaccord Genuity Medical Technology and Diagnostics Forum. The presentation by Taylor C. Harris, Vice President and Chief Financial Officer, will begin at 11:00 a.m., Eastern Standard Time ( 8:00 a.m., Pacific Standard Time). A webcast of the presentation will be available at http://wsw.com/webcast/canaccord12/, or on the company's website at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at http://www.thoratec.com.Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.